Makieieva N. I., Andrushchenko V. V.

IMBALANCE BETWEEN IL-2, IL-4 AND IFN-γ AS A MARKER OF SUSTAINABILITY OF PARTLY CONTROLLED ASTHMA IN CHILDREN

---

Show/Download

About the author:

Makieieva N. I., Andrushchenko V. V.

Heading:

PEDIATRICS

Type of article:

Scientific article

Annotation:

Asthma is one of the most common chronic diseases of childhood and adulthood. The pathogenetic mechanism of asthma is closely related to the functioning of cytokines. The aim of our study was to improve the knowledge on the assessment of cytokines (IL-2, IL-4, interferon-gamma) in the formation of chronic inflammation in children with partially controlled asthma. The study included 94 children who met the inclusion and exclusion criteria. The groups were formed depending on the severity of persistent asthma: 59 children with mild asthma - group 1; 10 children with moderate asthma - group 2; 12 children with severe asthma - group 3; 13 children from the control group - group 4. Cytokines were examined in children's serum using specific kits. IL-2, IL-4, and interferon-gamma were measured by a standard enzyme-linked immunosorbent assay. The study revealed the following data: all children with asthma had elevated levels of IL-2, IL-4 and reduced levels of interferon-gamma in the blood serum compared to the control group. The highest serum levels of IL-2, IL-4 and lowest IFN-γ were observed in patients with severe asthma. The correlation between cytokines and disease duration suggests that IL-2, IL-4 and IFN-γ may be considered as markers of chronic inflammation. The cytokine profile in children with persistent asthma in the exacerbation stage is characterised by elevated levels of IL-2 and IL-4 and decreased levels of IFN-γ in the blood serum. The data from our clinical study may lead us to the conclusion that there is an imbalance in the Th-1/Th-2 system.

Tags:

Bibliography:

1. Network GA. The Global Asthma Report. Auckland, New Zealand; 2018.
2. Hashmi MF, Tariq M, Cataletto ME. Asthma. StatPearls: Treasure Island; 2023.
3. GINA. The Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA). 2020. Available at: www ginasthma org.
4. Licari A, Castagnoli R, Brambilla I, Marseglia A, Tosca MA, Marseglia GL, et al. Asthma Endotyping and Biomarkers in Childhood Asthma. Pediatr Allergy Immunol Pulmonol. 2018 Jun 1;31(2):44-55. DOI: 10.1089/ped.2018.0886.
5. Gao H, Ying S, Dai Y. Pathological roles of neutrophil-mediated inflammation in asthma and its potential for therapy as a target. J Immunol Res. 2017;2017:3743048
6. Yu L, Li J. Punicalagin Alleviates Aged Bronchial Asthma by Inhibiting Th2 Differentiation through IL-4/STAT6 and Jagged1/Notch Pathways. J Healthc Eng. 2022 Jan 30;2022:1184677. DOI: 10.1155/2022/1184677.
7. Bravo-Solarte DC, Garcia-Guaqueta DP, Chiarella SE. Asthma in pregnancy. Allergy Asthma Proc. 2023 Jan 1;44(1):24-34. DOI: 10.2500/ aap.2023.44.220077.
8. Limb SL, Brown KC, Wood RA, Wise RA, Eggleston PA, Tonascia J, et al. Irreversible lung function deficits in young adults with a history of childhood asthma. J Allergy Clin Immunol. 2005 Dec;116(6):1213-9.
9. Gillissen A, Paparoupa M. Inflammation and infections in asthma. Clin Respir J. 2015 Jul;9(3):257-69. DOI: 10.1111/crj.12135.
10. Lambrecht BN, Hammad H, Fahy JV. The Cytokines of Asthma. Immunity. 2019 Apr 16;50(4):975-991. DOI: 10.1016/j.immuni.2019.03.018.
11. Liu C, Chu D, Kalantar-Zadeh K, George J, Young HA, Liu G. Cytokines: From Clinical Significance to Quantification. Adv Sci (Weinh). 2021 Aug;8(15):e2004433. DOI: 10.1002/advs.202004433.
12. Boshtam M, Asgary S, Kouhpayeh S, Shariati L, Khanahmad H. Aptamers Against Pro- and Anti-Inflammatory Cytokines: A Review. Inflammation. 2017 Feb;40(1):340-349. DOI: 10.1007/s10753-016-0477-1.
13. Monastero, RN, Pentyala, S. Cytokines as Biomarkers and Their Respective Clinical Cutoff Levels. Int. J. Inflammation. 2017;2017:4309485. DOI: 10.1155/2017/4309485.
14. Huang M, Mehrabi Nasab E, Athari SS. Immunoregulatory effect of mesenchymal stem cell via mitochondria signaling pathways in allergic asthma. Saudi J Biol Sci. 2021 Dec;28(12):6957-6962. DOI: 10.1016/j.sjbs.2021.07.071.
15. Xu C, Song Y, Wang Z, Jiang J, Piao Y, Li L, et al. Pterostilbene suppresses oxidative stress and allergic airway inflammation through AMPK/Sirt1 and Nrf2/HO-1 pathways. Immun Inflamm Dis. 2021 Dec;9(4):1406-1417. DOI: 10.1002/iid3.490.
16. Zhou JY, Alvarez CA, Cobb BA. Integration of IL-2 and IL-4 signals coordinates divergent regulatory T cell responses and drives therapeutic efficacy. Elife. 2021 Feb 22;10:e57417. DOI: 10.7554/eLife.57417.
17. León B. Understanding the development of Th2 cell-driven allergic airway disease in early life. Front Allergy. 2023 Jan 10;3:1080153. DOI: 10.3389/falgy.2022.1080153.
18. Lin JX, Leonard WJ. Fine-Tuning Cytokine Signals. Annu Rev Immunol. 2019 Apr 26;37:295-324. DOI: 10.1146/annurevimmunol-042718-041447.
19. Tinschert P, Rassouli F, Barata F, Steurer-Stey C, Fleisch E, Puhan MA, et al. Prevalence of nocturnal cough in asthma and its potential as a marker for asthma control (MAC) in combination with sleep quality: protocol of a smartphone-based, multicentre, longitudinal observational study with two stages. BMJ Open. 2019 Jan 7;9(1):e026323. DOI: 10.1136/bmjopen-2018-026323.
20. Zhang J, Zhao L, Zhao D, Chen Z, Li S, Zhang H, et al. Reliability and validity of the Chinese version of the Test for Respiratory and Asthma Control in Kids (TRACK) in preschool children with asthma: a prospective validation study. BMJ Open. 2019 Aug 26;9(8):e025378. DOI: 10.1136/bmjopen-2018-025378.
21. Fitzpatrick AM, Higgins M, Holguin F, Brown LA, Teague WG; National Institutes of Health/National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. The molecular phenotype of severe asthma in children. J Allergy Clin Immunol. 2010 Apr;125(4):851- 857.e18. DOI: 10.1016/j.jaci.2010.01.048.
22. Boonpiyathad S, Pornsuriyasak P, Buranapraditkun S, Klaewsongkram J. Interleukin-2 levels in exhaled breath condensates, asthma severity, and asthma control in nonallergic asthma. Allergy Asthma Proc. 2013 Sep-Oct;34(5):e35-41. DOI: 10.2500/aap.2013.34.3680. Erratum in: Allergy Asthma Proc. 2013 Nov-Dec;34(6):561.
23. Muralidharan A, Uddin MB, Bauer C, Wu W, Bao X, Sun K. IFN-γ Attenuates Eosinophilic Inflammation but Is Not Essential for Protection against RSV-Enhanced Asthmatic Comorbidity in Adult Mice. Viruses. 2022 Jan 14;14(1):147. DOI: 10.3390/v14010147.
24. Bolbot YuM, Taran OM. Osoblyvosti funktsionuvannia interferonovoi systemy u detei rannoho viku. Klinichna medytsyna. 2007;XII/4:72-78. in Ukrainian].
25. Pavord ID, Afzalnia S, Menzies-Gow ALG. The current and future role of biomarkers in type 2 cytokine-mediated asthma management. Heaney. 2017;47(2):148-160. DOI: https://doi.org/10.1111/cea.12881.
26. Syabbalo N. Biomarkers for Diagnosis and Management of Eosinophilic Asthma. Ann. Clin. Med. Res. 2020;1:1003.
27. Peters N, Peters AT. Atopic dermatitis. Allergy Asthma Proc. 2019 Nov 1;40(6):433-436. DOI: 10.2500/aap.2019.40.4265.
28. Nur Husna SM, Md Shukri N, Mohd Ashari NS, Wong KK. IL-4/IL-13 axis as therapeutic targets in allergic rhinitis and asthma. PeerJ. 2022 May 30;10:e13444. DOI: 10.7717/peerj.13444.
29. Hammad H, Lambrecht BN. The basic immunology of asthma. Cell. 2021 Mar 18;184(6):1469-1485. DOI: 10.1016/j.cell.2021.02.016. Erratum in: Cell. 2021 Apr 29;184(9):2521-2522.
30. Kottaiswamy A, Kizhakeyil A, Padmanaban AM, Mirza FB, Vijay VR, Lee PS, et al. The citrus flavanone hesperetin induces apoptosis in CTCL cells via STAT3/notch1/nf?b-mediated signaling Axis. Anti-Cancer Agents in Medicinal Chemistry. 2020;20(12):1459–1468. DOI: 10.2174/18715214096 66200324110031.
31. Makieieva N, Malakhova V, Vasylchenko Y, Tsymbal V. Are level of IL-13 and IL-4 predictive for formation of chronic inflammation in children with asthma? Adv Respir Med. 2020;88(4):320-326. DOI: 10.5603/ARM. a2020.0108.

Publication of the article:

«Bulletin of problems biology and medicine», 2023 Issue 3, 170, 433-438 pages, index UDC 616.248-053.2-078-092:612.017

DOI:

10.29254/2077-4214-2023-3-170-433-438